Joint venture · GCC · Announced 8 Nov 2026

Oman Investment Authority → Oryx Isotopes

Oman Investment Authority and Saudi Arabia's Oryx Isotopes launched Nucleus Oman, a joint venture to build Oman's first radiopharmaceutical production facility under a long-term PPP concession with the Ministry of Health, reported at OMR 6.5 million.

Parties: Oman Investment Authority (Oman) → Oryx Isotopes Company (Saudi Arabia)

Deal type
Joint venture
Value
$17m
Territory
Oman
Therapeutic area
Multi-therapy
Assets
Diagnostic radiopharmaceuticals; Targeted radionuclide therapy preparations
Announced
8 Nov 2026

Our analysis

Why this matters

Oman launched Nucleus Oman on 8 November 2026, the Sultanate's first radiopharmaceutical manufacturing project. A joint venture between the Oman Investment Authority (OIA) and Saudi Arabia's Oryx Isotopes Company will develop and operate it as concessionaire under a long-term public-private partnership with the Ministry of Health. The Ministers of Finance and Health and OIA President Abdulsalam bin Mohammed al Murshidi announced the project. WA-Gulf reports the investment at OMR 6.5 million (about US$17 million); the other reports give no figure, and none gives a location or timeline.

The facility will produce diagnostic radiopharmaceuticals for nuclear-medicine imaging in cancer, cardiovascular and neurological disease, with further units for targeted radionuclide therapy. It will also house a Secondary Standard Dosimetry Laboratory for calibrating radiation instruments, plus research and training facilities. The stated aim is to cut reliance on imports and give public and private hospitals a domestic supply.

The full analysis is free to read with a work email on this page.

Source: Oman Observer

Latest deals

All GCC deals → · All joint venture deals → · Browse all emerging-market pharma deals →